Dr. John Fruehauf provided an in-depth overview of treatments for metastatic melanoma. The primary outcomes of the study were melanoma-related deaths and nonmelanoma-related deaths. TPC2 and Rab7a interaction may be responsible for melanoma proliferation. Remote analysis of cancerous-looking skin growths yields the same level of accuracy as in-person analysis. Seventy-two percent of tumor specimens contained histologically defined LAs. The analysis included the CheckMate trials that involved ICI treatment-naive unresected/metastatic melanoma. Dr. John Fruehauf, Evolent, talks about a new standard of care in the treatment of stage III melanoma. The combo's use for conjunctival melanoma demonstrates the combinations high efficacy in treating complex disease. A novel method uses tumor-specific profiling to detect antibodies which are unique to early-stage melanoma. The combination therapy of sotiga with pembrolizumab is effective at treating patients with metastatic melanoma. A new study shows a notable decline in both melanoma incidence and mortality among young people in Sweden. Polygenic risk scores may serve as a viable tool to stratify patients based on their risk of invasive melanoma. Several studies have uncovered how immunotherapies work in concert to improve outcomes in patients with melanoma. Researchers conducted the first population-based survey of melanoma literacy in the United States. A factor secreted by tumor cells is responsible for the resistance of melanoma to treatment. One year of immunotherapy is optimal for treating patients with advanced melanoma. Medicaid expansion and improved access to health care services facilitate diagnosing melanoma at an early stage. Risk factors beyond sun exposure, including gene mutations, can influence a person's chances of developing melanoma. A new survey showed that too many young people believe myths and misinformation related to skin cancer prevention. DermaSensor announced this week that the US FDA cleared its AI-based handheld device for detecting skin cancer.